Interest of FDG-PET in the Management of Mantle Cell Lymphoma

Abstract : FDG-PET changed response assessment and therapy strategy in diffuse large B-cell lymphoma and Hodgkin disease lymphoma. The value of FDG-PET evaluation in MCL has not been extensively studied and a recent expert consensus highlighted the need for more studies addressing this question. Data of the literature show the value of FDG-PET at baseline in patients with MCL, underlining the good sensitivity of this examination for the initial staging of this pathology, but also the potential impact of semi-quantitative analysis in this indication. The determination of SUVmax at diagnosis might indeed provide important prognostic information. Some studies also suggest the potential value of early and end-of-treatment metabolic assessment in MCL, but these results need to be validated in standardized prospective studies. These results also underlie the need to integrate FDG-PET results into MCL treatment strategy to improve disease management in identifying patients who might benefit from more intensive therapy.
Document type :
Journal articles
Liste complète des métadonnées

https://www.hal.inserm.fr/inserm-02100231
Contributor : Elizabeth Bernardo <>
Submitted on : Monday, April 15, 2019 - 4:31:17 PM
Last modification on : Tuesday, April 16, 2019 - 1:30:14 AM

File

BaillyEq13-2019.pdf
Publisher files allowed on an open archive

Identifiers

Collections

Citation

Clément Bailly, Thomas Carlier, Cyrille Touzeau, Nicolas Arlicot, Françoise Kraeber-Bodéré, et al.. Interest of FDG-PET in the Management of Mantle Cell Lymphoma. Frontiers in Medicine, Frontiers media, 2019, 6, Epub ahead of print. ⟨10.3389/fmed.2019.00070⟩. ⟨inserm-02100231⟩

Share

Metrics

Record views

48

Files downloads

3